PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
17 hedge funds and large institutions have $6.98M invested in PLx Pharma Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.97% less ownership
Funds ownership: 24.65% → 23.67% (-0.97%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
39% less capital inflows, than outflows
Capital inflows: $877K | Capital outflows: $1.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$164K |
| 2 |
Renaissance Technologies
New York
|
+$36.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.88K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$4.18K |
| 5 |
Raymond James & Associates
St Petersburg,
Florida
|
+$3.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$651K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$536K |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$222K |
| 4 |
Heritage Way Advisors
Rockford,
Illinois
|
-$25.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$9K |
PLXP Hedge Fund Activity: Q1 2018 in Review
17 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2018, worth a combined $6.98M — down 39% from $11.4M a quarter earlier.
Fund positioning in PLXP was balanced in Q1 2018: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $164K. The largest seller was 683 Capital Management, cutting an estimated $651K.
- 17 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $6.98M of PLx Pharma Inc. Common Stock stock for Q1 2018, down 39% quarter-over-quarter.
- 3 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2018 and 3 closed out, a net change of 0 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q1 2018 was Vanguard Group, an estimated $164K added.
- The largest PLx Pharma Inc. Common Stock seller in Q1 2018 was 683 Capital Management, an estimated $651K sold.
Based on aggregated 13F filings for Q1 2018.